Robin Campbell

Dr. Robin Campbell is an Analyst at Equity Development Ltd., a Chairman at HemoGenyx Pharmaceuticals Plc and a Chief Investment Officer at NetScientific Plc.
Dr. Campbell has over 30 years of experience working with large companies.
Currently, his specialty is searching out investable opportunities in the broader life sciences sector, and helping small companies raise growth capital.
Dr. Campbell has helped list a number of companies onto the AIM and international exchanges, advised companies on secondary fundraisings, private equity raises, M&A and has a broad reach into institutional and retail investor networks.
Dr. Campbell was previously employed as a Research Analyst by Cantor Fitzgerald Europe, by Seymour Pierce Ltd., by ING Bank NV (United Kingdom), and by Jefferies International Ltd. (Old).
He also worked as Head of Life Sciences by Merchant Securities Ltd., a Global Head of Healthcare Research by Religare Capital Markets Plc, and an Analyst by ABN AMRO Hoare Govett and by WestLB Panmure Ltd. Dr. Campbell also worked at Credit Suisse Securities (Europe) Ltd., at GlaxoSmithKline Plc, and at Paribas Capital Markets.
He received his undergraduate degree from the University of London, a degree in Microbiology from King's College London and a PhD in Immunobiology from The University of Liverpool.